Document Detail

In vitro correction of a deficiency of Con A-induced suppressor cell function in primary biliary cirrhosis by a pharmacological concentration of colchicine.
MedLine Citation:
PMID:  6235989     Owner:  NLM     Status:  MEDLINE    
Patients with primary biliary cirrhosis (PBC) have been previously reported to have immunoregulatory abnormalities. We tested the effect of in vitro colchicine on PBC patients' suppressor cell function in order to determine whether colchicine can correct their suppressor cell deficiency. PBC patients' mononuclear cells were cultured for 44 h with concanavalin A (Con A) as well as with or without colchicine at a pharmacological concentration (10(-8)M) or at a suprapharmacological concentration (10(-5)M) and then tested for their ability to suppress proliferation of phytohaemagglutinin stimulated healthy volunteers' mononuclear cells. Eleven PBC patients had significantly (P less than 0.001) decreased suppressor cell function (12 +/- 15%, mean +/- s.d.) as compared to 37 healthy volunteers (43 +/- 12%). The suprapharmacological concentration of colchicine did not significantly affect the PBC patients' suppressor cell function (16 +/- 15%). In contrast, in the nine PBC patients tested with the pharmacological concentration of colchicine, their suppressor cell function was increased to 40 +/- 20% which was significantly different than without colchicine (P less than 0.01) or with the suprapharmacological concentration of colchicine (P = 0.02) but not significantly different than healthy volunteers. Thus, in vitro colchicine at a pharmacological concentration corrects PBC patients' deficiency of Con A-induced suppressor cell function raising the possibility that oral colchicine might be clinically useful as an immunomodulating drug in PBC.
D Ilfeld; E Theodor; G Delpre; O Kuperman
Related Documents :
15534869 - Paradigmatic identification of mmp-2 and mt1-mmp activation systems in cardiac fibrobla...
7747779 - Mild phenotypic effects of a de novo deletion xpter-->xp22.3 and duplication 3pter-->3p23.
16247459 - Merlin facilitates ubiquitination and degradation of transactivation-responsive rna-bin...
9813719 - A differential pcr system for the determination of ccnd1 (cyclin d1) gene amplification...
15164769 - The abc's of group iv cytosolic phospholipase a2.
6396019 - Kb cells for antinuclear antibody determination: comparison with hep-2 cells and the cr...
11407859 - Not all muscles meet the same fate when they die.
24288769 - Immunohistochemical study of a- and b-cell distribution in human pancreatic langerhans ...
21808189 - Induction of g2/m phase arrest and apoptosis by potent antitumor apca in human cervix c...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental immunology     Volume:  57     ISSN:  0009-9104     ISO Abbreviation:  Clin. Exp. Immunol.     Publication Date:  1984 Aug 
Date Detail:
Created Date:  1984-10-02     Completed Date:  1984-10-02     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0057202     Medline TA:  Clin Exp Immunol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  438-42     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Colchicine / administration & dosage,  pharmacology*
Concanavalin A / pharmacology
Liver Cirrhosis, Biliary / immunology*
Middle Aged
T-Lymphocytes, Regulatory / drug effects*
Reg. No./Substance:
11028-71-0/Concanavalin A; 64-86-8/Colchicine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tumour-induced suppressor macrophages in rats: differences in their suppressive effects on the Con A...
Next Document:  Humoral and cellular immune response of the rat to immunization with bee venom.